Actinium Pharmaceuticals, Inc. 在2026年美国癌症研究协会年会上公布了其候选药物ATNM-400的引人注目的泛癌种研究数据。该数据表明,ATNM-400在前列腺癌、肺癌以及乳腺癌临床前模型中均显示出广泛的抗肿瘤疗效。
Actinium Pharmaceuticals, Inc. 在2026年美国癌症研究协会年会上公布了其候选药物ATNM-400的引人注目的泛癌种研究数据。该数据表明,ATNM-400在前列腺癌、肺癌以及乳腺癌临床前模型中均显示出广泛的抗肿瘤疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.